EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Molecular Diagnostic Yield and Safety Profile of Ultrasound-Guided Lung Biopsies: A Cross-Sectional Study

Vito D'Agnano, Fabio Perrotta, Giulia Maria Stella iD, Raffaella Pagliaro iD, Filippo De Rosa, Francesco Saverio Cerqua, Angela Schiattarella, Edoardo Grella, Umberto Masi, Luigi Panico, Andrea Bianco iD, Carlo Iadevaia

Cancers · 16.08.2024 · 16 (16) · 2860

DOI: 10.3390/cancers16162860 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Cancers, online erschienen am 16.08.2024. Verfasst von Vito D'Agnano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, University of Campania L. Vanvitelli, 80131 Naples, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The recent advances in precision oncology for lung cancer treatment has focused attention on the importance of obtaining appropriate specimens for tissue diagnosis as well as comprehensive molecular profiling. CT scan-guided biopsies and bronchoscopy are currently the main procedures employed for tissue sampling. However, growing evidence suggests that ultrasound-guided biopsies may represent an effective as well as safe approach in this diagnostic area. This study explores the safety and the diagnostic yield for cancer molecular profiling in ultrasound-guided percutaneous lung lesion biopsies (US-PLLB).

Methods

One hundred consecutive patients with suspected lung cancer, between January 2021 and May 2024, who had ultrasound-guided lung biopsies have been retrospectively analyzed. Molecular profiling was conducted with next-generation sequencing Genexus using Oncomine precision assay or polymerase chain reaction according to specimen quality. Qualitative immunohistochemical assay of programmed death ligand 1 (PD-L1) expression was evaluated by the Dako PD-L1 immunohistochemistry 22C3 pharmDx assay. The co-primary endpoints were the molecular diagnostic yield and the safety profile of US-guided lung biopsies.

Results

From January 2021 to May 2024, 100 US-guided lung biopsies were carried out and 95 were considered for inclusion in the study. US-PLLB provided informative tissue for a histological evaluation in 93 of 95 patients with an overall diagnostic accuracy of 96.84% [Sensitivity: 92.63%; Specificity: 96.84%; PPV: 100%; NPV: 100%]. Sixty-Six patients were diagnosed with NSCLC (69.47%) and were considered for molecular diagnostic yield evaluation and PD-L1 testing. Four patients had malignant lymphoid lesions. US-PLLB was not adequate to achieve a final diagnosis in three patients (3.16%). Complete molecular profiling and PD-L1 evaluation were achieved in all patients with adenocarcinoma (molecular diagnostic yield: 100%). PD-L1 evaluation was achieved in 28 of 29 patients (96.55%) with either SCC or NOS lung cancer. The overall complication rate was 9.47% (n = 9). Six patients (6.31%) developed pneumothorax, while three patients (3.16%) suffered mild haemoptysis without desaturation.

Conclusions

According to our findings, US-guided lung biopsy is a safe, minimally invasive procedure in patients with suspected lung malignancies, providing an excellent diagnostic yield for both comprehensive molecular profiling and PD-L1 testing. In addition, our results suggest that US-guided biopsy may also be an effective diagnostic approach in patients with suspected lung lymphoma.

Schlagwörter

Stichwörter der Autor:innen

PD-L1biopsydiagnosislung cancerpathologytargeted therapyultrasound

Autor:innen und Institutionen

  • Department of Translational Medical Sciences, University of Campania L. Vanvitelli, 80131 Naples, Italy.
  • U.O.C. Clinica Pneumologica L. Vanvitelli, Monaldi Hospital, A.O. dei Colli, 80131 Naples, Italy.
  • Unit of Respiratory Diseases, Department of Medical Sciences and Infective Diseases, IRCCS Policlinico San Matteo Foundation, University of Pavia Medical School, 27100 Pavia, Italy.
  • Unit of Pathology Monaldi Hospital, A.O. dei Colli, 80131 Naples, Italy.

ORCID-Profile: Giulia Maria Stella, Raffaella Pagliaro, Andrea Bianco

Zitieren

APA

D'Agnano, V., Perrotta, F., Stella, G. M., Pagliaro, R., De Rosa, F., Cerqua, F. S., Schiattarella, A., Grella, E., Masi, U., Panico, L., Bianco, A., & Iadevaia, C. (2024). Molecular Diagnostic Yield and Safety Profile of Ultrasound-Guided Lung Biopsies: A Cross-Sectional Study. Cancers, 16(16), 2860. https://doi.org/10.3390/cancers16162860

Vancouver

D'Agnano V, Perrotta F, Stella GM, Pagliaro R, De Rosa F, Cerqua FS, et al. Molecular Diagnostic Yield and Safety Profile of Ultrasound-Guided Lung Biopsies: A Cross-Sectional Study. Cancers. 2024;16(16):2860. doi:10.3390/cancers16162860

BibTeX
@article{DAgnano2024,
  author = {D'Agnano, Vito and Perrotta, Fabio and Stella, Giulia Maria and Pagliaro, Raffaella and De Rosa, Filippo and Cerqua, Francesco Saverio and Schiattarella, Angela and Grella, Edoardo and Masi, Umberto and Panico, Luigi and Bianco, Andrea and Iadevaia, Carlo},
  title = {Molecular Diagnostic Yield and Safety Profile of Ultrasound-Guided Lung Biopsies: A Cross-Sectional Study},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {16},
  pages = {2860},
  doi = {10.3390/cancers16162860}
}
Kostenlos starten →